Background: Tuberculosis screening is recommended in multiple sclerosis patients starting certain disease-modifying therapies. Disease-modifying therapies may affect interferon-gamma release assay results. Objective: To determine the effects of multiple sclerosis disease-modifying therapies on interferongamma release assay results. Methods: Indeterminate interferon-gamma release assay results among multiple sclerosis patients were compared across disease-modifying therapies by Fisher's exact test. Logistic regression evaluated the effects of lymphopenia on interferon-gamma release assay results. Results: A total of 1058 patients underwent interferon-gamma release assay: 2.0% (21) positive, 6.1% (65) indeterminate, with 59.4% (628) on disease-modifying therapies. Results were significantly different across disease-modifying therapies (P ¼ 0.002). Absolute lymphocyte count less than 0.5 k/lL had 9.39 times (95% confidence interval 5.2-17.0) increased odds of indeterminate interferon-gamma release assay results. Conclusions: Disease-modifying therapies affecting lymphocytes had a higher risk of indeterminate interferon-gamma release assay results.
Introduction
Disease modifying therapies (DMTs) for multiple sclerosis (MS) have diverse effects on the immune system, and can increase the risk of latent tuberculosis (TB) reactivation. 1 TB screening is recommended prior to the initiation of certain DMTs, 1 but generally occurs in the setting of prior DMTs. TB screening, including by serum interferon-gamma release assay (IGRA), is affected by immunosuppression. [2] [3] [4] One study examined the in vitro effects of teriflunomide on IGRA in latent TB; teriflunomide led to conversion from positive to negative. 5 The effect of MS DMTs on IGRA has not otherwise been investigated.
In latent or active TB infection, T cells are sensitized to TB-specific antigens. IGRA measures interferon-gamma release in response to TBspecific antigen exposure in vitro (antigen response). 6 The mitogen response determines the adequacy of serum T-cell response as a positive control. Patients with anergy or lymphocyte hyporesponsiveness can have a false negative or indeterminate test.
Our study objectives were to determine the frequency of positive or indeterminate IGRA testing in a MS clinic population and the effects of DMTs on IGRA. 
Patients and methods
(IU/mL)), and absolute lymphocyte count (ALC, k/lL) within 30 days. Follow-up testing for indeterminate IGRAs were recorded. Approval from the Cleveland Clinic institutional review board was obtained (#18-094).
Statistical analysis
Proportions of patients with indeterminate IGRA were compared across DMTs by Fisher's exact testing. Logistic regression determined the odds of indeterminate testing in the setting of specific DMTs, steroid use, or grade 3 or greater lymphopenia (ALC <0.5 k/lL). Spearman's rank correlation coefficient was calculated for ALC and mitogen response. All analyses were performed using R (version 3.5.2).
Results

Patient population
A total of 1058 patients with MS who underwent TB testing by IGRA were included (Table 1) . Generally, patients underwent IGRA prior to starting a DMT for which screening is standard practice at our center (ocrelizumab, teriflunomide, alemtuzumab). (Figure 1 ). Mitogen response was coded as 11 if it was reported as greater than 10 (lab standard); this ceiling effect could impact the interpretability of results.
Conclusions
This is the first study to report the effects of several MS DMTs on IGRA results, specifically investigating which increase the likelihood of an indeterminate result. Grade 3 or worse lymphopenia, recent methylprednisolone use, and fingolimod or DMF use significantly increased the odds of indeterminate IGRA. Indeterminate results were driven by inadequate mitogen response in the setting of lymphopenia, which is not unexpected in the setting of medications known to interfere with lymphocyte trafficking and function. Further testing is needed in patients on certain DMTs who have a higher clinical suspicion of TB or are from endemic regions.
Our results are similar to those obtained in the literature regarding DMTs for systemic autoimmune conditions. Studies indicate impaired IGRA response and indeterminate results are associated with corticosteroids, tumor necrosis factor antagonists, and other immunosuppressive therapies.
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In a large MS center in the United States, fewer than 10% of patients had abnormal IGRA results: 2.0% were positive and 6.1% indeterminate. This latent TB prevalence by way of IGRA is similar to national estimates of 0.6% to 4.8% from the 2011-2012
National Health and Nutrition Examination Survey. 9, 10 However, our population included few potentially vaccinated patients, so we cannot comment on the effect of DMTs or lymphopenia on IGRA results in this population. Individual TB exposure risk factors were not available.
Clinicians should be aware of the factors affecting IGRA results, as adequate screening for latent TB is crucial for safety with certain DMTs. In the setting of indeterminate Quantiferon-TB Gold IGRA results, the T-SPOT.TB assay may decrease susceptibility of testing to immunocompromise. 8 However, TB screening is most sensitively completed in patients not on DMTs. Our retrospective study was limited to patients on or starting DMTs, but IGRA testing pre and post-DMT exposure is needed to evaluate better how individual DMTs affect IGRA results. Sampling bias may impact result generalizability, as mandatory TB screening for certain DMTs (e.g. teriflunomide, alemtuzumab) may have resulted in their underrepresentation in this study. Further work is needed to determine optimal TB screening methods in low-risk, potentially immunocompromised patient populations such as MS.
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